![Iressa (gefitinib) has been approved by the U.S. Food and Drug Administration to treat patients with metastatic non-small-cell lung cancer with a specific genetic mutation (epidermal growth factor receptor [EGFR]). A just-approved companion diagnostic test can identify patients who could benefit from this new use.](https://www.ehealth-news.com/wp-content/uploads/2016/01/fdalogo-6-180x84.jpg "FDA Approves Iressa for EGFR+ Metastatic Lung Cancer")
FDA Approves Iressa for EGFR+ Metastatic Lung Cancer
New companion diagnostic kit can identify candidates
CDC: Most Americans in Favor of Raising Legal Smoking Age to 21
Even 70 percent of smokers support the concept
Non-AIDS In-Hospital Deaths Up in HIV-Infected Patients
Non-AIDS infections and cardiovascular disease are common causes of mortality in the ART era
ASCO Endorses ASTRO Guidelines for Endometrial Cancer
Qualifications to guidelines include stronger statements in favor of chemotherapy in some cases
Benefits of Extended Anticoagulation May Not Last
New study suggests that oral anticoagulant meds may be needed for the very long term
Pockets of U.S. Have Excessive Colorectal Cancer Mortality
Areas include parts of the Mississippi Delta, Appalachia, and eastern Virginia
Surveillance Becoming More Common for Prostate Cancer
Many men with low-risk disease being spared prostatectomy, radiation, androgen deprivation tx
Genetic Mutations May Impact Outcomes in Aplastic Anemia
Genetic evaluation may help predict prognosis in aplastic anemia
Mortality Rates Declining for Many Cancers
Rates predicted to meet Healthy People 2020 targets for breast, lung, prostate cancers
Regular Mammograms May Lead to Widespread Overdiagnosis
No significant difference in breast cancer deaths for counties with higher screening, detection rates
